NONINVASIVE PRENATAL TESTING:

How Can You Apply New Screening Methods and Updated Guidance for Use in Your Clinical Practice?

To create your own poster, please visit

HTTPS://NIPT.POSTERPROGRAM.COM

Noninvasive Prenatal Testing: How Can You Apply New Screening Methods and Updated Guidance for Use in Your Clinical Practice?

Resource	Address
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. ACOG Practice Bulletin, Number 226. Screening for Fetal Chromosomal Abnormalities. *Obstet Gynecol*. 2020;136:e48-e69.	https://pubmed.ncbi.nlm.nih.gov/32804883/
Bardsley MZ, et al. 47,XYY syndrome: Clinical phenotype and timing of ascertainment. *J Pediatr*. 2013;163:1085-1094.	https://pubmed.ncbi.nlm.nih.gov/23810129/
Benn P, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn*. 2015;35:725-734.	https://pubmed.ncbi.nlm.nih.gov/25970088/
Bianchi DW, et al. DNA Sequencing versus standard prenatal aneuploidy screening. *N Engl J Med.* 2014;370:799-808.	https://www.nejm.org/doi/full/10.1056/nejmoa1311037
Bianchi DW. Pregnancy: Prepare for unexpected prenatal test results. *Nature.* 2015;522:29-30.	https://pubmed.ncbi.nlm.nih.gov/26040879/
Canick JA, et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. *Prenat Diag* 2013;33:667-674.	https://pubmed.ncbi.nlm.nih.gov/23592541/
Committee opinion o. 640: Cell-free DNA screening for fetal aneuploidy. *Obstet Gynecol*. 2015;126:e31-e37.	https://pubmed.ncbi.nlm.nih.gov/26287791/
Gil MM, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: Updated meta-analysis.	https://pubmed.ncbi.nlm.nih.gov/28397325/

Ultrasound Obstet Gynecol. **2017;50:302-314.**	
Guy C, et al. Prenatal cell-free DNA screening for fetal aneuploidy in pregnant women at average or high risk: Results from a large US clinical laboratory. *Mol Genet Genomic Med*. 2019 Mar;7:e545.	https://pubmed.ncbi.nlm.nih.gov/30706702/
Kitzman JO, et al. Noninvasive whole-genome sequencing of a human fetus. *Sci Transl Med*. 2012;4:137ra76.	https://pubmed.ncbi.nlm.nih.gov/22674554/
Lo YM, et al. Presence of fetal DNA in maternal plasma and serum. *Lancet*. 1997;350:485-487.	https://pubmed.ncbi.nlm.nih.gov/9274585/
Niles KM, et al. Prolonged duration of persistent cell-free fetal DNA from vanishing twin. *Ultrasound Obstet Gynecol* 2018;52:547-548.	https://pubmed.ncbi.nlm.nih.gov/29330885/
Norwitz ER, et al. Validation of a single-nucleotide polymorphism-based non-invasive prenatal test in twin gestations: Determination of zygosity, individual fetal sex, and fetal aneuploidy. *J Clin Med.* 2019;8:937.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679081/
Pergament E, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. *Obstet Gynecol*. 2014;124(2 Pt 1):210-218.	https://pubmed.ncbi.nlm.nih.gov/25004354/
Ross JL, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. *N Engl J Med*. 2011;364:1230-1242.	https://www.nejm.org/doi/full/10.1056/nejmoa1005669
Scott FP, et al. Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. *J Matern Fetal Neonatal Med*. 2018;31:1865-1872.	https://pubmed.ncbi.nlm.nih.gov/28514925/
Shook LL, et al. High fetal fraction on first trimester cell-free DNA aneuploidy screening and adverse pregnancy outcomes. *Am J Perinatol.* 2020;37:8-13.	https://pubmed.ncbi.nlm.nih.gov/31365936/

Spencer K, et al. First trimester aneuploidy screening in the presence of a vanishing twin: Implications for maternal serum markers. *Prenat Diagn.* 2010;30:235-240.	https://pubmed.ncbi.nlm.nih.gov/20066674/
Valderramos SG, et al. Cell-free DNA screening in clinical practice: Abnormal autosomal aneuploidy and microdeletion results. *Am J Obstet Gynecol.* 2016;215:626.e1-626.e10.	https://pubmed.ncbi.nlm.nih.gov/27371353/
Vora NL, et al. Utility of ultrasound examination at 10-14 weeks prior to cell-free DNA screening for fetal aneuploidy. *Ultrasound Obstet Gynecol*. 2017;49:465-469.	https://pubmed.ncbi.nlm.nih.gov/27300317/
Yaron Y, et al. Maternal plasma genome-wide cell-free DNA can detect fetal aneuploidy in early and recurrent pregnancy loss and can be used to direct further workup. *Hum Reprod*. 2020;35:1222-1229.	https://pubmed.ncbi.nlm.nih.gov/32386059/

Resources and Societies

Resource	Address
American Board of Genetic Counseling	https://www.abgc.net/
American College of Obstetricians and Gynecologists	https://www.acog.org/
International Society for Prenatal Diagnosis	https://www.ispdhome.org/
National Society of Genetic Counselors	https://www.nsgc.org/
Society for Maternal-Fetal Medicine	https://www.smfm.org/
The Fetal Medicine Foundation	https://fetalmedicine.org/